RecruitingNCT07278310
STAR Trial (Siegel Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis)
AI Description
To evaluate the safety and efficacy of Siegel™ TAVR System in the treatment of subjects with symptomatic severe native aortic stenosis.
- Who can join
- adult, older adult
- Participants
- 1025
- Expected completion
- 2028-04
- Funded by
- industry
Conditions studied
Aortic Stenosis, Symptomatic Severe Native Aortic Stenosis
What is being tested
- DEVICE: Siegel TAVR Device
- DEVICE: TAVR Device
What it measures
- All-cause mortality, all stroke and cardiovascular rehospitalization, The primary endpoint is the composite of all-cause mortality, all stroke, and cardiovascular rehospitalization (valve-related or procedure-related per VARC-3) at 1 year., 1 Year
Centers Participating
These centers are participating in this study. Reach out to them directly to learn more.
Registry entry updated 2026-04-09
Deciding whether to join a study is your choice, and you can ask a study team questions before you decide anything.
If you would rather we did it with you, call us on (656) 206-4686.